Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, BGI Ink Pact to Co-develop and Sell Arrays for Agricultural Research

Premium

By Justin Petrone

This article has been updated from a version posted Jan. 13 to include comments from Affymetrix and BGI officials.

Affymetrix and BGI last week announced a deal that will see the life sciences tool vendor and the Chinese genomics organization co-develop and co-market microarrays for agricultural applications.

The non-exclusive partnership will aim to provide a portfolio of plant, crop, and livestock microarrays for genotyping analysis, spanning applications such as marker-assisted trait selection, parentage, quality control, and traceability.

The partners will use BGI's next-generation sequencing platforms, bioinformatics capabilities, and sequencing databases to develop new content for Affy's genotyping arrays. Specifically, the collaboration will rely on data from the 1000 Plant and Animal Reference Genomes Project, initiated by BGI in 2010.

Jasmine Gruia-Gray, Affy's vice president of global marketing, told BioArray News that the firm partnered with BGI to "increase its footprint in the plant and animal genomics market." She said that arrays could be available in the second or third quarter.

BGI and Affy will co-market the resulting products, though the targeted SNP arrays will be commercialized through Affy's channels, meaning that the arrays can be run by customers in their facilities or can be run by Affy as a service, or through independent service providers that have the company's platforms, Gruia-Gray said.

BGI and Affy will also promote BGI's next-generation sequencing services together with Affy's microarrays as "complementary platforms" for plant and animal genomics researchers.

According to Gruia-Gray, this is the first time that Affy has worked with BGI. The institute already offers targeted genotyping services on Illumina BeadChips and Sequenom's MassArray platform, according to its website.

Jun Wang, BGI's executive director, said in a statement that the new collaboration with Affy will "help advance the application of genomic selection to scientists seeking to improve outcomes in breeding plants, crops, and livestock."

"We look forward to making plant and animal sequencing data more widely available to the global agricultural community," he added.

BGI spokesperson Bicheng Yang told BioArray News that the institute is in "very early-stage discussions" with Affy, and declined to further discuss the new deal.

BGI has partnered with companies on array-related projects in the past. Last August, BGI discussed a partnership with Paris-based Exonhit Therapeutics to use Exonhit's splice variant array platform, which is manufactured by Affy, to study gene deregulation and identify biomarkers in a "strategic preclinical animal model species" that both partners declined to name (BAN 8/2/2011).


Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.